10.31.14
Alkermes
3Q Revenues: $160.0 million (+14%)
3Q Loss: $40.0 million (loss of $7.8 million 3Q13)
YTD Revenues: $443.6 million (flat)
YTD Loss: $60.6 million (earnings were $2.6 million YTD13)
Comments: Manufacturing and royalty revenues for the long-acting atypical antipsychotic franchise, RISPERDAL CONSTA and INVEGA SUSTENNA/XEPLION, were $68.5 million in the quarter, up 9%. Manufacturing and royalty revenues from AMPYRA/FAMPYRAwere $16.5 million, up 31%. Sales of VIVITROL were $25.8 million, up 34%. Royalty revenue from BYDUREON was $10.3 million, up 46%.
3Q Revenues: $160.0 million (+14%)
3Q Loss: $40.0 million (loss of $7.8 million 3Q13)
YTD Revenues: $443.6 million (flat)
YTD Loss: $60.6 million (earnings were $2.6 million YTD13)
Comments: Manufacturing and royalty revenues for the long-acting atypical antipsychotic franchise, RISPERDAL CONSTA and INVEGA SUSTENNA/XEPLION, were $68.5 million in the quarter, up 9%. Manufacturing and royalty revenues from AMPYRA/FAMPYRAwere $16.5 million, up 31%. Sales of VIVITROL were $25.8 million, up 34%. Royalty revenue from BYDUREON was $10.3 million, up 46%.